Evolution of Biologics Screening Technologies
AbstractScreening for biologics, in particular antibody drugs, has evolved significantly over the last 20 years. Initially, the screening processes and technologies from many years experience with small molecules were adopted and modified to suit the needs of biologics discovery. Since then, antibody drug discovery has matured significantly and is today investing earlier in new technologies that commercial suppliers are now developing specifically to meet the growing needs of large molecule screening. Here, we review the evolution of screening and automation technologies employed in antibody discovery and highlight the benefits that these changes have brought. View Full-Text
Share & Cite This Article
Cariuk, P.; Gardener, M.J.; Vaughan, T.J. Evolution of Biologics Screening Technologies. Pharmaceuticals 2013, 6, 681-688.
Cariuk P, Gardener MJ, Vaughan TJ. Evolution of Biologics Screening Technologies. Pharmaceuticals. 2013; 6(5):681-688.Chicago/Turabian Style
Cariuk, Peter; Gardener, Matthew J.; Vaughan, Tristan J. 2013. "Evolution of Biologics Screening Technologies." Pharmaceuticals 6, no. 5: 681-688.